Patent granted for Orpyx technology in Australia

Intellectual Property Protection Extends to Another Market

Calgary, AB Canada, September 28, 2016 - Orpyx Medical Technologies Inc. announced today that the Australian Patents Office has awarded Orpyx the “Peripheral Sensory and Supersensory Replacement System.” The patent covers key inventions used in both Orpyx’s SurroSense Rx (R) product and future products, such as SurroGait Rx (TM), in Australia.

“We are thrilled to see our innovations recognized by the Australia Patents Office,” said Dr. Breanne Everett, CEO of Orpyx Medical Technologies Inc. “The continued growth of our intellectual property portfolio reinforces our leadership in sensor-based wound care solutions.”

SurroSense Rx is designed to actively prevent the complications associated with diabetic peripheral neuropathy. The system is worn by the patient in the shoe, and a proprietary smartwatch provides real-time alerts when dangerous levels of pressure threaten to cause permanent damage to the patient’s tissue. This allows him or her to offload that pressure and avoid the development of pressure ulcers. Additionally, data is uploaded to the cloud and, over time, tracks the patient’s compliance and predicts areas of concern.

The SurroGait Rx system is comprised of sensor-embedded inserts that are worn inside running or walking shoes, and an ergonomic back display worn on the user’s back. Pressure information collected from the insert is wirelessly sent to the back display, which transposes sensation that would otherwise be felt on the foot onto the back, so that the user can “feel” their feet through the back. The SurroGait Rx system is designed to enable improved gait and balance and decrease the risk of falls inherent to the problem of not being able to properly feel the feet.

About Orpyx Medical Technologies Inc.
Orpyx Medical Technologies Inc. (“Orpyx”) is a wearable pressure sensor technology company focused on medical applications. Orpyx’s primary intention is to address the world’s growing epidemic of diabetes and its associated complications, most notably, peripheral neuropathy, which leads to lack of circulation, numbness, or loss of protective sensation, in the feet. This problem leads to the development of foot ulcers which can ultimately lead to amputation and death infection and ulcers in the feet, also known as peripheral neuropathy. Additionally, this problem affects upwards of 60% of diabetics over the course of their disease and costs the North American health care system over $16.4 billion annually.

For more information, please contact:
Chan Mean
Marketing Manager, Orpyx Medical Technologies Inc.
chan.mean@orpyx.com
+1 403 460 0216 ext. 501




Chan Mean
Chan Mean

Author